IL-2 antibody induction and the outcome of pediatric renal trasplants (original) (raw)

2002, Transplantation Proceedings

AI-generated Abstract

The study investigates the impact of IL-2 receptor antagonists, basiliximab and daclizumab, on acute rejection rates in pediatric renal transplant recipients. Despite high initial acute rejection rates in this demographic, the addition of these monoclonal antibodies to standard immunosuppressive regimens resulted in a significantly reduced incidence of acute rejection and favorable graft function outcomes after 6 months. Notably, no severe adverse effects were directly associated with the administration of IL-2 receptor antagonists, highlighting their potential safety and efficacy in this setting.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact